The development of highly specific T-cell engagers directed against pHLA tumor targets will be quick and easy. BioCopy's innovative pHLA screening technology characterizes drug candidates in great depth for their specific binding against the desired pHLA tumor target. YUMAB develops highly specific antibodies with their advanced antibody technologies.

Breath test replaces invasive diagnostics - 30/07/2025

Novel smartphone sensor offers innovative breath test to detect Helicobacter infection

The stomach bacterium Helicobacter pylori is widespread and, if left undetected, can impact our well-being and also lead to serious health conditions. While effective treatments exist, a reliable diagnosis is essential. To address this, researchers have developed an affordable breath test that uses a mini-sensor to detect the presence of the bacterium. They are currently working on a smartphone-compatible version for self-testing.

The rapid increase in antibiotic-resistant bacteria is one of the most pressing challenges facing global health. A new transatlantic Fraunhofer research project aims to counter these threats with an innovative diagnostic approach: a microfluidic rapid test system using carbon nanotubes (SWCNT) will make bacterial resistance visible in just a few minutes, significantly faster than conventional methods.

A method developed at the Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB enables bacterial, viral, fungal, or parasitic pathogens in sepsis patients to be identified much faster than before and with the highest precision. The approach is based on high-throughput sequencing of cell-free DNA circulating in the blood and was honored with the EARTO Innovation Award in the "Impact Delivered" category on October 14,…

The European Commission has today proposed an ambitious package of measures to improve the health of EU citizens, while ensuring the long-term resilience and competitiveness of the health sector.

Robotics in medicine - 15/02/2024

Copied from the pangolin: innovative flexible miniature robot for minimally invasive applications

Wireless miniature robots that can penetrate hard-to-reach areas of the body for the purpose of medical treatment are currently still a vision of the future. Researchers at the Max Planck Institute for Intelligent Systems in Stuttgart have now constructed the first flexible prototype modelled on the pangolin, which can generate heat and stop bleeding, kill tumour cells or release "cargo" in the model system.

At a time of geopolitical tensions and growing supply shortages, surgical capability is becoming a critical factor for resilient health systems. Hellstern medical GmbH has been accepted into the NATO DIANA innovation program with its key technology, the Robotic Surgeon Assist noac — NATO’s accelerator for defense and dual-use technologies.

At the new Institute for Adaptive Mechanical Systems (IAMS) at the University of Stuttgart, the focus is on a new generation of walking robots and “soft robotics”. The researchers are developing adaptable robots inspired by natural movement patterns and made from innovative soft materials. The applications range from healthcare and industrial production to energy supply.

Novel coronavirus outbreak - a status report on recent developments - 04/03/2020

Waiting for a SARS-CoV-2 vaccine

Researchers around the world are working frantically on the development of a vaccine against the new coronavirus. A project by the Tübingen-based biotechnology company CureVac, funded by the Coalition for Epidemic Preparedness Innovations (CEPI), uses the company’s technology platform for mRNA-based vaccines to accelerate vaccine development, thus contributing to the future prevention of the disease.

With the "Česká Hlava" awards, the Czech government has been honoring the country's most brilliant minds every year since 2002 and recognizing exceptional achievements in research, development and innovation. Martina Benešová-Schäfer of the German Cancer Research Center was among the six laureates honored in 2022 at Charles University in Prague.

Winfried Kretschmann, the Minister President of Baden-Württemberg, Germany, visited the Max Planck Institutes for Biology Tübingen and Biological Cybernetics. During his tour, he commended the outstanding basic research in the natural sciences. He was particularly impressed by the innovative research projects spanning developmental and evolutionary biology, as well as neuroscience.

New treatment methods: DNA origami-based nanodevices precisely control immune response - 24/04/2025

Bottom-up synthetic immunology for novel therapeutic approaches

Modern therapies for combating cancer and infectious diseases increasingly leverage the body’s own immune system. Several research groups at Heidelberg University are using innovative bottom-up approaches in synthetic immunology to develop new treatment methods that can control the immune response more precisely than previously possible.

Baden-Württemberg receives the EU Commission's "Regional Innovation Valley" label - 01/07/2024

Customised healthcare for all: BIOPRO is a partner in the EU project PRECISEU

The EU research project PRECISEU, which started in June 2024 and will run for five years, aims to connect innovation ecosystems across Europe and advance personalised medicine throughout Europe. BIOPRO Baden-Württemberg is one of 25 partner organisations from 11 European countries that are working on the further development of customised healthcare as part of the research project.

At the finale of the Cyber Valley Days, and Science Minister Petra Olschowski opened the ELLIS Institute Tübingen, heralding the next phase of the AI Innovation Campus. With the world's first ELLIS Institute, Cyber Valley is gaining further radiance. Olschowski also announced at the ceremony that the Karlsruhe Institute of Technology (KIT) is joining the Cyber Valley Community.

SICOS BW GmbH - 18/06/2020

High-performance computing and data analytics to combat coronavirus

In an epidemic, data exchange and the use of innovative technologies are essential to be able to act effectively and quickly against the infection. High-performance computers and data analytics make a valuable contribution to this. SICOS BW is a promising solution centre that bridges the gap from numerical simulation, big data and AI to companies in the medical technology sector.

Inside the fight against COVID-19 - 28/10/2020

A new immunotherapeutic agent for treating severe COVID-19 cases

Apogenix, a Heidelberg-based biopharmaceutical company specialising in innovative immunotherapeutics, has initiated a Phase II clinical trial with asunercept, the company’s lead drug candidate for treating severe cases of COVID-19. The fusion protein blocks the CD95-ligand-mediated death of epithelial cells in the lung and thus prevents damage to the organ.

Heidelberg University is to acquire a research building to develop innovative engineering science strategies and technologies on the basis of life-inspired molecular systems. The German Science and Humanities Council has now expressed its backing for the idea with an outstanding rating. This recommendation is the crucial precondition for a new building on the university campus Im Neuenheimer Feld.

Five transnational and cross-institutional doctoral networks at Heidelberg University are being funded as part of the “Marie Skłodowska-Curie Actions”. They work together on current scientific topics with high innovation potential. Ruperto Carola coordinates an MSCA Doctoral Network on artificial intelligence in physics, two networks in medicine, life sciences and engineering.

The German Center for Mental Health (DZPG) conducts nationwide research on individualized treatments for depression, anxiety disorders, and addiction. Its approach combines established therapeutic methods with innovative strategies to enhance overall treatment efficacy. The primary beneficiaries are patients for whom conventional therapies have so far proven insufficiently effective.

Creating scope for innovative projects from various disciplines: That is the aim of the research incubators at Ulm University. The aim is to initiate developments and ideas that could become relevant research areas for the University. In the current call for proposals, the jury has selected two interdisciplinary projects on quantum chemistry and digital, sensor-based diabetes research.

VERAXA Biotech AG, an emerging leader in designing novel cancer therapies, today announced that its previously announced business combination (“Business Combination”) with Voyager Acquisition Corp. (NASDAQ: VACH, “Voyager”), a special purpose acquisition company sponsored by Cantor Fitzgerald & Co., Voyager Acquisition Sponsor Holdco LLC, and Odeon Capital Group LLC, was closed successfully (the “Closing”)

As a dominant part of southern Germany’s life-science industry hub, Heidelberg will soon have a life-science startup incubator of its own. BioLabs, the premier US network of managed co-working lab space, will open its first German branch in the Heidelberg Innovation Park (hip). On August 16, representatives of city and state governments, BioLabs and the life-science industry celebrated the Heidelberg BioLabs groundbreaking.

Printing a new cornea during an operation to restore a patient’s eyesight: This groundbreaking step in the fight against corneal disorders is set to become reality with a laser based process using personalized bioink. The method was developed by researchers at the Karlsruhe Institute of Technology (KIT) in collaboration with Carl Zeiss Meditec AG and Evonik Healthcare. Their project won the idea award in this year’s NEULAND innovation contest.

Dossier - 10/09/2012

Horizon 2020 the EU framework programme for research and innovation a boost for top-level research in Europe

In the face of the ongoing financial crisis Europe is working on a new research strategy that is aimed at creating new economic growth and jobs. The new EU framework programme for research and innovation Horizon 2020 replaces the 7th Framework Programme FP7 and will run from 2014 with a budget of 80 billion. In July 2012 Brussels launched the final FP7 calls for proposals for 2013 that offer numerous market-based instruments designed to bridge…

Lab-on-a-chip - 11/11/2020

Microfluidic platform for the best possible cancer therapy

Every tumour and every patient is different, and there are individual reactions to drugs as well as the problem of resistance. Patient-specific cancer treatments require innovative and cost-effective approaches. The TheraMe! consortium has developed a novel instrument: a combination of microfluidic experiments and mathematical modelling for use in cancer precision medicine to prevent incorrect therapy options.